Repression of PCGF1 Decreases the Proliferation of Glioblastoma Cells in Association with Inactivation of c-Myc Signaling Pathway

References

• Weller M, Wick W, Aldape K, et al. Glioma. Nat Rev Dis Primers. 2015;1:15017. doi:10.1038/nrdp.2015.1727188790
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-127157931
   PubMed Web of Science ®Google Scholar
• Hatoum A, Mohammed R, Zakieh O. The unique invasiveness of glioblastoma and possible drug targets on extracellular matrix. Cancer Manag Res. 2019;11:1843–1855. doi:10.2147/CMAR.S18614230881112
   PubMed Web of Science ®Google Scholar
• Peng H, Li Z, Fu J, Zhou R. Growth and differentiation factor 15 regulates PD-L1 expression in glioblastoma. Cancer Manag Res. 2019;11:2653–2661. doi:10.2147/CMAR.S19209531114328
   PubMed Web of Science ®Google Scholar
• Syed M, Liermann J, Verma V, et al. Survival and recurrence patterns of multifocal glioblastoma after radiation therapy. Cancer Manag Res. 2018;10:4229–4235. doi:10.2147/CMAR30323678
   PubMed Web of Science ®Google Scholar
• Ren Z, Liang J, Zhang P, Chen J, Wen J. Inhibition of human glioblastoma cell invasion involves PION@E6 mediated autophagy process. Cancer Manag Res. 2019;11:2643–2652. doi:10.2147/CMAR.S20015131015768
   PubMed Web of Science ®Google Scholar
• Pan SJ, Zhan SK, Pan YX, et al. Tetraspanin 8-rictor-integrin alpha3 complex is required for glioma cell migration. Int J Mol Sci. 2015;16(3):5363–5374. doi:10.3390/ijms1603536325761241
   PubMed Web of Science ®Google Scholar
• Chen Z, Xu N, Zhao C, Xue T, Wu X, Wang Z. Bevacizumab combined with chemotherapy vs single-agent therapy in recurrent glioblastoma: evidence from randomized controlled trials. Cancer Manag Res. 2018;10:2193–2205. doi:10.2147/CMAR30087578
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro-Oncology. 2014;16(7):896–913. doi:10.1093/neuonc/nou08724842956
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466. doi:10.1016/S1470-2045(09)70025-719269895
   PubMed Web of Science ®Google Scholar
• Cuddapah VA, Robel S, Watkins S, Sontheimer H. A neurocentric perspective on glioma invasion. Nat Rev Neurosci. 2014;15(7):455–465. doi:10.1038/nrn376524946761
   PubMed Web of Science ®Google Scholar
• Liang Z, Wang Y, Li H, Sun Y, Gong Y. lncRNAs combine and crosstalk with NSPc1 in ATRA-induced differentiation of U87 glioma cells. Oncol Lett. 2019;17(6):5821–5829. doi:10.3892/ol.2019.1025431186810
   PubMed Web of Science ®Google Scholar
• Ross K, Sedello AK, Todd GP, et al. Polycomb group ring finger 1 cooperates with Runx1 in regulating differentiation and self-renewal of hematopoietic cells. Blood. 2012;119(18):4152–4161. doi:10.1182/blood-2011-09-38239022411870
   PubMed Web of Science ®Google Scholar
• Wu XD, Zhang M, Gong YH, et al. [Expression pattern of polycomb gene Nspc1 at the early developmental stage in zebrafish]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2008;30(5):550–553.19024384
   PubMedGoogle Scholar
• Li H, Fan R, Sun M, Jiang T, Gong Y. Nspc1 regulates the key pluripotent Oct4-Nanog-Sox2 axis in P19 embryonal carcinoma cells via directly activating Oct4. Biochem Biophys Res Commun. 2013;440(4):527–532. doi:10.1016/j.bbrc.2013.09.09524113379
   PubMed Web of Science ®Google Scholar
• Yan Y, Zhao W, Huang Y, et al. Loss of polycomb group protein Pcgf1 severely compromises proper differentiation of embryonic stem cells. Sci Rep. 2017;7:46276. doi:10.1038/srep4627628393894
   PubMed Web of Science ®Google Scholar
• Cao G, Gu M, Zhu M, et al. Bmi-1 absence causes premature brain degeneration. PLoS One. 2012;7(2):e32015. doi:10.1371/journal.pone.003201522363787
   PubMed Web of Science ®Google Scholar
• He S, Iwashita T, Buchstaller J, Molofsky AV, Thomas D, Morrison SJ. Bmi-1 over-expression in neural stem/progenitor cells increases proliferation and neurogenesis in culture but has little effect on these functions in vivo. Dev Biol. 2009;328(2):257–272. doi:10.1016/j.ydbio.2009.01.02019389366
   PubMed Web of Science ®Google Scholar
• Hong Y, Shang C, Xue YX, Liu YH. Silencing of Bmi-1 gene enhances chemotherapy sensitivity in human glioblastoma cells. Med Sci Monit. 2015;21:1002–1007. doi:10.12659/MSM.89375425858624
   PubMed Web of Science ®Google Scholar
• Kong Y, Ai C, Dong F, et al. Targeting of BMI-1 with PTC-209 inhibits glioblastoma development. Cell Cycle. 2018;17(10):1199–1211. doi:10.1080/15384101.2018.146987229886801
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Stetson L, Virk SM, Barnholtz-Sloan JS. Epidemiology of gliomas. Cancer Treat Res. 2015;163:1–14.25468222
   PubMedGoogle Scholar
• Schneider T, Mawrin C, Scherlach C, Skalej M, Firsching R. Gliomas in adults. Dtsch Arztebl Int. 2010;107(45):799–807; quiz 8. doi:10.3238/arztebl.2010.0799
   Google Scholar
• Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell. 2010;7(3):299–313. doi:10.1016/j.stem.2010.08.00220804967
   PubMed Web of Science ®Google Scholar
• Mathews LA, Crea F, Farrar WL. Epigenetic gene regulation in stem cells and correlation to cancer. Differentiation. 2009;78(1):1–17. doi:10.1016/j.diff.2009.04.00219443100
   PubMed Web of Science ®Google Scholar
• Ma L, Lin K, Chang G, et al. Aberrant activation of beta-catenin signaling drives glioma tumorigenesis via USP1-mediated stabilization of EZH2. Cancer Res. 2019;79(1):72–85. doi:10.1158/0008-5472.CAN-18-130430425057
   PubMed Web of Science ®Google Scholar
• Isshiki Y, Nakajima-Takagi Y, Oshima M, et al. KDM2B in polycomb repressive complex 1.1 functions as a tumor suppressor in the initiation of T-cell leukemogenesis. Blood Adv. 2019;3(17):2537–2549. doi:10.1182/bloodadvances.201802852231471323
   PubMed Web of Science ®Google Scholar
• Deng Q, Hou J, Feng L, et al. PHF19 promotes the proliferation, migration, and chemosensitivity of glioblastoma to doxorubicin through modulation of the SIAH1/beta-catenin axis. Cell Death Dis. 2018;9(11):1049. doi:10.1038/s41419-018-1082-z30323224
   PubMedGoogle Scholar
• Cheng T, Xu Y. Effects of Enhancer of Zeste Homolog 2 (EZH2) expression on brain glioma cell proliferation and tumorigenesis. Med Sci Monit. 2018;24:7249–7255. doi:10.12659/MSM.90981430305602
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen H, Zhu H, Sun X. CBX8 promotes tumorigenesis and confers radioresistance in esophageal squamous cell carcinoma cells through targeting APAF1. Gene. 2019;711:143949. doi:10.1016/j.gene.2019.14394931255735
   PubMed Web of Science ®Google Scholar
• Li G, Warden C, Zou Z, et al. Altered expression of polycomb group genes in glioblastoma multiforme. PLoS One. 2013;8(11):e80970. doi:10.1371/journal.pone.008097024260522
   PubMed Web of Science ®Google Scholar
• Zhang J, Xu S, Xu J, et al. miR7675p inhibits glioma proliferation and metastasis by targeting SUZ12. Oncol Rep. 2019;42(1):55–66. doi:10.3892/or.2019.715631115583
   PubMed Web of Science ®Google Scholar
• Sun J, Zhang L, Zhao H, et al. CHD1L regulates cell cycle, apoptosis, and migration in glioma. Cell Mol Neurobiol. 2016;36(4):565–576. doi:10.1007/s10571-015-0237-z26162969
   PubMed Web of Science ®Google Scholar
• Chukkapalli S, Amessou M, Dekhil H, et al. Ehd3, a regulator of vesicular trafficking, is silenced in gliomas and functions as a tumor suppressor by controlling cell cycle arrest and apoptosis. Carcinogenesis. 2014;35(4):877–885. doi:10.1093/carcin/bgt39924306026
   PubMed Web of Science ®Google Scholar
• Li X, Wu C, Chen N, et al. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget. 2016;7(22):33440–33450. doi:10.18632/oncotarget.796126967052
   PubMedGoogle Scholar
• Zhao HF, Wang J, Shao W, et al. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Cancer. 2017;16(1):100. doi:10.1186/s12943-017-0670-328592260
   PubMed Web of Science ®Google Scholar
• Kalhori MR, Irani S, Soleimani M, Arefian E, Kouhkan F. The effect of miR-579 on the PI3K/AKT pathway in human glioblastoma PTEN mutant cell lines. J Cell Biochem. 2019;120(10):16760–16774. doi:10.1002/jcb.v120.1031243804
   PubMed Web of Science ®Google Scholar
• Zhang X, Zheng K, Li C, et al. Nobiletin inhibits invasion via inhibiting AKT/GSK3beta/beta-catenin signaling pathway in Slug-expressing glioma cells. Oncol Rep. 2017;37(5):2847–2856. doi:10.3892/or.2017.552228339056
   PubMed Web of Science ®Google Scholar
• Atkins RJ, Stylli SS, Luwor RB, Kaye AH, Hovens CM. Glycogen synthase kinase-3beta (GSK-3beta) and its dysregulation in glioblastoma multiforme. J Clin Neurosci. 2013;20(9):1185–1192. doi:10.1016/j.jocn.2013.02.00323768967
   PubMed Web of Science ®Google Scholar
• Kotliarova S, Pastorino S, Kovell LC, et al. Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res. 2008;68(16):6643–6651. doi:10.1158/0008-5472.CAN-08-085018701488
   PubMed Web of Science ®Google Scholar
• Tian T, Mingyi M, Qiu X, Qiu Y. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3beta in glioblastoma. Oncotarget. 2016;7(48):79584–79595. doi:10.18632/oncotarget.1286127792996
   PubMedGoogle Scholar
• Nowicki MO, Dmitrieva N, Stein AM, et al. Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. Neuro-Oncology. 2008;10(5):690–699. doi:10.1215/15228517-2008-04118715951
   PubMed Web of Science ®Google Scholar
• Hu YH, Kong SQ, Kong HB, Wu JL, Chen Z. Targeting c-Myc on cell growth and vascular endothelial growth factor expression in IN500 glioblastoma cells. Chin Med J. 2012;125(11):2025–2031.22884072
   PubMed Web of Science ®Google Scholar
• Guo P, Nie Q, Lan J, Ge J, Qiu Y, Mao Q. C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells. Biochem Biophys Res Commun. 2013;441(1):186–190. doi:10.1016/j.bbrc.2013.10.03424140063
   PubMed Web of Science ®Google Scholar
• Ishida CT, Shu C, Halatsch ME, et al. Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma. Oncotarget. 2017;8(23):37140–37153. doi:10.18632/oncotarget.1620228415755
   PubMedGoogle Scholar
• Wang T, Chen W, Wu J. H2-P, a honokiol derivative, exerts anti-angiogenesis effects via c-MYC signaling pathway in glioblastoma. J Cell Biochem. 2018;119(4):3142–3148. doi:10.1002/jcb.v119.429080353
   PubMed Web of Science ®Google Scholar
• Liu W, Lv G, Li Y, Li L, Wang B. Downregulation of CDKN2A and suppression of cyclin D1 gene expressions in malignant gliomas. J Exp Clin Cancer Res. 2011;30:76. doi:10.1186/1756-9966-30-7621843312
   PubMed Web of Science ®Google Scholar
• Holmes B, Lee J, Landon KA, et al. Mechanistic target of rapamycin (mTOR) inhibition synergizes with reduced internal ribosome entry site (IRES)-mediated translation of cyclin D1 and c-MYC mRNAs to treat glioblastoma. J Biol Chem. 2016;291(27):14146–14159. doi:10.1074/jbc.M116.72692727226604
   PubMed Web of Science ®Google Scholar
• Xu Z, Zeng X, Tian D, et al. MicroRNA-383 inhibits anchorage-independent growth and induces cell cycle arrest of glioma cells by targeting CCND1. Biochem Biophys Res Commun. 2014;453(4):833–838. doi:10.1016/j.bbrc.2014.10.04725450356
   PubMed Web of Science ®Google Scholar
• Wang J, Wang Q, Cui Y, et al. Knockdown of cyclin D1 inhibits proliferation, induces apoptosis, and attenuates the invasive capacity of human glioblastoma cells. J Neurooncol. 2012;106(3):473–484. doi:10.1007/s11060-011-0692-421912938
   PubMed Web of Science ®Google Scholar
• Wang C, Zhao N, Zheng Q, Zhang D, Liu Y. BHLHE41 promotes U87 and U251 cell proliferation via ERK/cyclinD1 signaling pathway. Cancer Manag Res. 2019;11:7657–7672. doi:10.2147/CMAR.S21469731616182
   PubMed Web of Science ®Google Scholar
• PS H, Xia QS, Wu F, et al. NSPc1 promotes cancer stem cell self-renewal by repressing the synthesis of all-trans retinoic acid via targeting RDH16 in malignant glioma. Oncogene. 2017;36(33):4706–4718. doi:10.1038/onc.2017.3428394339
   PubMed Web of Science ®Google Scholar